Alpha-MSH comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
=== Early guerrilla incursions === In November 1960, Ethiopia and Liberia had formally petitioned the ICJ for a binding judgment, rather than an advisory opinion, on whether South Africa remained fit to govern South West Africa. Both nations emphasised that they considered the implementation of apartheid to be a violation of Pretoria's obligations as a mandatory power. The National Party government rejected the claim on the grounds that Ethiopia and Liberia lacked sufficient legal interest to present a case concerning South West Africa. This argument suffered a major setback on 21 December 1962 when the ICJ ruled that, as former League of Nations member states, both parties had a right to institute the proceedings. Around March 1962, SWAPO President Sam Nujoma visited the party's refugee camps across Tanzania, describing his recent petitions for South West African independence at the Non-Aligned Movement and the UN. He pointed out that independence was unlikely in the foreseeable future, predicting a "long and bitter struggle". Nujoma personally directed two exiles in Dar es Salaam, Lucas Pohamba and Elia Muatale, to return to South West Africa, infiltrate Ovamboland and send back more potential recruits for SWALA. Over the next few years, Pohamba and Muatale successfully recruited hundreds of volunteers from the Ovamboland countryside, most of whom were shipped to Eastern Europe for guerrilla training. Between July 1962 and October 1963 SWAPO negotiated military alliances with other anti-colonial movements, namely in Angola.
microfilament A long, thin, flexible, rod-like structure composed of polymeric strands of proteins, usually actins, that occurs in abundance in the cytoplasm of eukaryotic cells, forming part of the cytoskeleton. Microfilaments comprise the cell's structural framework. They are modified by and interact with numerous other cytoplasmic proteins, playing important roles in cell stability, motility, contractility, and facilitating changes in cell shape, as well as in cytokinesis.
Supercritical water oxidation Photodegradation Sonochemical oxidation Electrochemical oxidation Plasma treatment Hydrothermal alkaline treatment Incineration Private and public sector applications of one or more of these methodologies above are being applied to remediation sites throughout the United States and other international locations. The U.S.-based Interstate Technology and Regulatory Council (ITRC) has undertaken an extensive evaluation of ex-situ and in-situ treatment technologies for PFAS-impacted liquid matrices. These technologies are divided into field-implemented technologies, limited application technologies, and developing technologies and typically fit into one of three technology types, namely separation, concentration, and destruction.
Sources: en.wikipedia.org
=== Design === A single-layer concrete paver has been utilized for the whole 15-metre width of the concrete slabs on either side of the road. The expressway will be designed to serve as a runway for airplanes to facilitate fast incident response in war-like situations, emergencies, or natural disasters. An Integrated Traffic Management System will be deployed along the expressway to keep tabs on vehicles speeding, lane discipline, or vehicular breakdowns. At every 40–50 km of interval on the e-way, wayside amenities like food plazas and rest areas along with electric charging stations for electric vehicles will be made available. Extensive landscaping, tunnel lighting, bridge beautification, improved street lighting, and digital signage will be used throughout the length of the expressway. Amongst the 32 major bridges that shall be built along the expressway, 5 bridges at Nagpur, Wardha, Nashik, Buldhana, and Thane are proposed to have a theme-based iconic design. To ensure digital readiness and resource availability, provisions will be laid down for optical fiber connectivity, natural gas pipelines, and electricity grid along the Mahamarg at industrial townships. With electric vehicle charging points proposed at prospecting locations along the expressway and solar plants planned to generate 250MW energy, the Samruddhi Corridor aims to become a model of an energy efficient corridor. Maximum locally available material, fly ash and plastic will be used to construct the expressway wherever possible.
A human chimera is a human with a subset of cells with a distinct genotype than other cells, that is, having genetic chimerism. An organism that contains a mixture of human and non-human cells would be a human–animal chimera.
Their large size and fearsome reputation make them popular zoo exhibits. In the wild, their range has been reduced by human encroachment and is likely to contract further from the effects of climate change; hence, they are listed as Endangered by the IUCN Red List. They are protected under Indonesian law, and the Komodo National Park was founded in 1980 to aid protection efforts. In the Komodo language, the dragons are called sebae 'twins' out of a traditional belief by the Komodo people that they share the same spiritual mother as the dragons. Meanwhile, the Baar people, who speak the Baar dialect of Riung language, call the Komodo dragon mbau.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.